MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of a Phase I clinical study for its in-house developed antibiotic, MRX-5, in Australia. This new benzodiazole antibiotic is designed to treat infections caused by Mycobacterium, with a particular focus on non-tuberculosis Mycobacterium (NTM).
The Phase I study, conducted at the Nucleus Network in Australia, assessed the safety, tolerability, pharmacokinetic characteristics, and food effects of MRX-5 in healthy adult subjects following single and multiple oral administrations. The results demonstrated that MRX-5 showed good safety and tolerability within the healthy adult population, with adverse events being predominantly mild and manageable.
Within the dose range of 50mg to 1200mg, the pharmacokinetics of the active metabolite MRX-6038 in healthy subjects after a single oral dose of MRX-5 were found to be linear and predictable. Preliminary data from food impact studies suggest that MRX-6038 is not influenced by food intake.- Flcube.com
